|1.||Hohmann, Andrea G: 3 articles (07/2015 - 09/2010)|
|2.||Deng, Liting: 2 articles (07/2015 - 01/2014)|
|3.||Beaulieu, Pierre: 2 articles (02/2014 - 06/2006)|
|4.||Makriyannis, Alexandros: 2 articles (01/2014 - 11/2009)|
|5.||Kianian, Mandana: 2 articles (01/2013 - 01/2012)|
|6.||Lehmann, Christian: 2 articles (01/2013 - 01/2012)|
|7.||Guindon, Josée: 2 articles (09/2010 - 06/2006)|
|8.||Zimmer, Andreas: 2 articles (01/2010 - 04/2009)|
|9.||Stepanovic-Petrovic, Radica M: 1 article (12/2015)|
|10.||Tomic, Maja A: 1 article (12/2015)|
03/01/2007 - "Pretreatment with the CB(1) receptor subtype-selective antagonist AM 251 completely abolished the antinociceptive effect of WIN 55,212-2 whereas pretreatment with the CB(2) receptor subtype-selective antagonist AM 630 did not alter the antinociceptive effect of WIN 55,212-2. These data indicate that a CB(1)-selective agonist may be novel therapeutic treatment for clinical SCI pain."
12/01/2015 - "The influence of 5-HT1B/1D serotonin receptor (GR 127935) and CB1 (AM251) and CB2 cannabinoid receptor (AM630) antagonists on the antinociceptive effect of ESL was tested in the model of trigeminal pain. "
03/01/2014 - "Administration of CB2 receptor agonist JWH133 before ischemia significantly improved the recovery of cardiac ventricular function during reperfusion, increased coronary flow, reduced infarct size, prevented the loss of ΔΨ(m) and MPTP opening, reduced the release of cytochrome c from mitochondria, and increased levels of p-ERK1/2. These effects of JWH133 were abolished by pretreatment with CB2 receptor antagonist AM630, or ERK1/2 inhibitor PD98059. "
03/01/2010 - "In conclusion, this study provides the evidence that blockage of CB2 with AM630 can markedly reduce Ti particle induced osteolysis in a murine air pouch model. "
03/01/2010 - "The aim of the current study was to determine whether CB2 selective antagonist (AM630) inhibits wear debris-induced osteolysis in a murine osteolysis model. "
03/01/2010 - "This finding points to the possibility that CB2 selective antagonists like AM630 may have potential value for prevention and treatment of wear particle induced osteolysis."
03/01/2010 - "AM630 inhibited Ti particle-induced osteolysis associated gene activity of RANK, RANKL and CPK, and diminished RANKL expression in Ti particle stimulated pouches. "
10/01/2010 - "Inhibition of titanium particle-induced inflammatory osteolysis through inactivation of cannabinoid receptor 2 by AM630."
08/01/2011 - "Intrathecal administration of JWH015 dose dependently attenuated tumor-evoked tactile allodynia and thermal hyperalgesia but this effect was prevented by intrathecal administration of AM630 30 minutes before. "
01/01/2010 - "We then administered concomitant CB(1) and CB(2) receptor antagonists/inverse agonists (AM281 and AM630, 1 mg x kg(-1) each, i.p.) during the acute phase of paw incision-induced mechanical allodynia and evaluated the expression of glial cell markers and phosphorylated p38 (a MAPK associated with inflammation) in the lumbar dorsal horn. "
02/01/2014 - "Mechanical allodynia and thermal hyperalgesia were evaluated in 436 male C57BL/6, cnr1KO and cnr2KO mice in the presence or absence of cannabinoid CB₁ (AM251) or CB₂ (AM630) receptor antagonists in a mouse model of neuropathic pain. "
01/01/2014 - "WIN55,212-2-mediated suppression of mechanical hypersensitivity was dominated by CB1 activation whereas suppression of cold allodynia was relatively insensitive to blockade by either CB1 (AM251; 3 mg/kg/day s.c.) or CB2 (AM630; 3 mg/kg/day s.c.) antagonists. "
07/01/2015 - "High-dose CP55,940 (10 mg/kg daily, i.p.) produced catalepsy in WT mice, which precluded determination of antiallodynic efficacy but produced sustained CB2-mediated suppression of paclitaxel-induced allodynia in CB1KO mice; these antiallodynic effects were blocked by the CB2 antagonist 6-iodopravadoline (AM630). "
|1.||AM 251 (AM251)
|2.||CB2 Cannabinoid Receptor
|3.||Win 55212-2 (WIN 55,212)
|4.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
|8.||Cannabinoid Receptors (Cannabinoid Receptor)
|10.||CB1 Cannabinoid Receptor (CB1 Receptor)